Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database

14Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objectives: Hepatocellular carcinoma (HCC) associated with major vascular invasion is an advanced stage disease with an extremely poor prognosis and low survival rate. Our study evaluated the survival benefit of radiotherapy (RT) in HCC patients with major vascular invasion through Surveillance, Epidemiology, and End Results database. Methods: We analyzed 3181 HCC patients with major vascular invasion cases diagnosed from 2004 to 2013. Patients (N = 308) who underwent RT and patients (N = 2873) who did not receive RT were compared. We successfully analyzed patients using propensity score matching (PSM). Kaplan-Meier and Cox-regression analyses were applied to assess prognosis. Results: The median survival time in radiation-treated group was longer compared to the control group (7 months vs 3 months; P < 0.001) in the overall sample and 3 months longer compared to the control group (7 months vs 4 months; P < 0.001) in a PSM cohort. Cox-regression analyses showed that radiation-treated patients in propensity-matched sample had a significantly lower risk of mortality (HR: 0.625, 95% CI: 0.522-0.749, P < 0.001) compared with untreated patients. The radiation-treated groups had better survival rate than untreated group. Subgroup analysis revealed that the survival time of patients in radiation-treated group was significantly longer than that in the untreated group (P < 0.001 and P = 0.026, respectively). The subgroup analysis also revealed that RT provides a survival benefit regardless of race, marital status, and tumor size after PSM. Conclusions: Radiotherapy provides improves survival in HCC patients with major vascular invasion, especially for tumor(s) confined to one lobe and not on surface of liver.

References Powered by Scopus

Global cancer statistics, 2012

25688Citations
N/AReaders
Get full text

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

23782Citations
N/AReaders
Get full text

Sorafenib in advanced hepatocellular carcinoma

10633Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

456Citations
N/AReaders
Get full text

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

16Citations
N/AReaders
Get full text

Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Lin, Q., Huang, X., Zhong, C., Luo, T., Zeng, X., & Chen, S. (2019). Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database. Cancer Medicine, 8(2), 515–526. https://doi.org/10.1002/cam4.1937

Readers' Seniority

Tooltip

Professor / Associate Prof. 1

50%

PhD / Post grad / Masters / Doc 1

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

50%

Nursing and Health Professions 1

50%

Save time finding and organizing research with Mendeley

Sign up for free